ePRO Technology Benefits Drug Development for Pulmonary Diseases

ePRO Technology Benefits Drug Development for Pulmonary Diseases 150 150 Biomedical & Health Informatics (BHI)

The quest to find new therapies to treat and cure pulmonary disease continues at a rapid pace. According to Centerwatch.com, 27,583 pulmonary studies are ongoing. Asthma studies represent more than 10% of these trials. Chronic obstructive pulmonary disease (COPD) studies make up less than 1% of ongoing studies, but it is the fourth leading cause of death worldwide.

Read more on the link.